Scientists reprogram immune cells to hunt down common cancer mutations
NCT ID NCT06484790
Summary
This is a first-in-human study testing a new type of personalized cell therapy for people with advanced solid tumors that have specific KRAS mutations (G12V or G12D). The therapy involves collecting a patient's own immune cells (T cells), genetically engineering them in a lab to recognize and attack cancer cells with these mutations, and then infusing them back into the patient. The main goals of this early-phase trial are to find a safe dose and see if the treatment shows any early signs of shrinking tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.